公开(公告)号：KR101078890B1

公开(公告)日：2011-11-01

申请号：KR1020097022222

申请日：2008-03-24

Applicant: 고려대학교 산학협력단

Inventor： 김재홍 ,  조경진 ,  유민혁

IPC: A61K38/00 ,  A61K31/41 ,  A61P11/06 ,  A61K39/395

CPC classification number: C12N15/1138 ,  A61K31/41 ,  C07K14/705 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315

Abstract: 본발명자들은뮤린모델을이용하여천식의병인에서 BLT2의역할을조사하고안티센스올리고뉴클레오티드와같은, BLT2 저해제를사용함으로서 BLT2가 AHR 및기도염증의발달에결정적인역할을함을증명하였다. 따라서, 본발명에따른 BLT2 저해제는천식치료를위한치료학적조성물로서효과적으로사용될수 있다.

公开(公告)号：KR1020090125837A

公开(公告)日：2009-12-07

申请号：KR1020097022222

申请日：2008-03-24

Applicant: 고려대학교 산학협력단

Inventor： 김재홍 ,  조경진 ,  유민혁

IPC: A61K38/00 ,  A61K31/41 ,  A61P11/06 ,  A61K39/395

CPC classification number: C12N15/1138 ,  A61K31/41 ,  C07K14/705 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/315

Abstract: PURPOSE: A pharmaceutical composition for treating asthma, which contains an inhibitor of leukotriene B4 receptor BLT2 is provided to suppress NF-kappa B activation and treat asthma. CONSTITUTION: An inhibitor of leukotriene B4 receptor BLT2 is used in producing drug for treating asthma by suppressing expression or intracellular signal transduction of BLT2. The BLT2 inhibitor is LY255283(1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]-ethanone). The BLT2 inhibitor is antibody to BLT2, which suppresses intracellular signal transduction. The pharmaceutical composition for treating asthma contains a material which suppresses expression or activation of Rac as an active ingredient.

Abstract translation: 目的：提供一种用于治疗哮喘的药物组合物，其含有白三烯B4受体BLT2的抑制剂以抑制NF-κB活化和治疗哮喘。 构成：通过抑制BLT2的表达或细胞内信号转导，将白三烯B4受体BLT2的抑制剂用于制备治疗哮喘的药物。 BLT2抑制剂为LY255283（1- [5-乙基-2-羟基-4 - [[6-甲基-6-（1H-四唑-5-基）庚基]氧基]苯基] - 乙酮）。 BLT2抑制剂是BLT2的抗体，其抑制细胞内信号转导。 用于治疗哮喘的药物组合物含有抑制作为活性成分的Rac的表达或活化的材料。